Endothelium-Derived Relaxing Factor (EDRF) induced vasodilatation is mediated by
## **Core Concept**
Endothelium-Derived Relaxing Factor (EDRF) is a substance released by the endothelium that causes underlying smooth muscle to relax, leading to vasodilation. The most well-known EDRF is nitric oxide (NO). The release of EDRF/NO plays a critical role in vascular tone regulation.
## **Why the Correct Answer is Right**
The correct answer, , is right because **Nitric Oxide (NO)** is the primary EDRF. It is synthesized from L-arginine by the enzyme **endothelial nitric oxide synthase (eNOS)** in the endothelial cells. NO then diffuses into the smooth muscle cells, activating **guanylyl cyclase**, which increases intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP levels lead to smooth muscle relaxation and subsequent vasodilation.
## **Why Each Wrong Option is Incorrect**
- **Option A:** - This option is incorrect because prostacyclin, though a product of endothelial cells and a vasodilator, is not the primary EDRF. It works by increasing cAMP levels in smooth muscle cells, not through the NO-cGMP pathway.
- **Option B:** - This option is incorrect as endothelium-derived hyperpolarizing factor (EDHF) does cause vasodilation but through hyperpolarization of smooth muscle cells, not through the NO-cGMP pathway.
- **Option D:** - This option is incorrect because endothelin is actually a potent vasoconstrictor produced by endothelial cells, not a vasodilator.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **nitric oxide (NO) donors**, such as nitroglycerin, work by mimicking the action of EDRF/NO. They are used clinically to induce vasodilation, particularly in the treatment of angina pectoris. Understanding the NO-cGMP pathway is crucial for appreciating the mechanism of action of various cardiovascular drugs.
## **Correct Answer:** . Nitric oxide